Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Lixisenatide vs Tirzepatide: they're closely matched on evidence (5 vs 7.8/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Lixisenatide and Tirzepatide are closely matched across evidence, studies, and safety.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (2)
Outcomes where both Lixisenatide and Tirzepatide have evidence — compare verdict strength side-by-side.
Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.
morning
Subcutaneous once-daily injection (Adlyxin / Lyxumia)
Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)
any
Once-weekly subcutaneous injection (Mounjaro / Zepbound)
Weeks (24-week endpoints)
Per meal / weeks
Months
Median 25 months
Weeks to months
Months (dose-escalated over ~20 weeks)
Weeks to months
Mostly during titration
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA).
N Engl J Med (2015) · Rct · n=6068
Cardiovascular-outcomes RCT: 6,068 patients with type 2 diabetes and a recent acute coronary syndrome (MI or unstable angina within 180 days), lixisenatide vs placebo added to usual care, median 25 months
Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Diabetes Care (2012) · Rct · n=361
Phase-3 double-blind 12-week RCT, 361 drug-naive patients with type 2 diabetes randomized to lixisenatide (two titration regimens) or placebo
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Diabetes Care (2013) · Rct · n=495
Phase-3 double-blind RCT, 495 patients on established basal insulin with inadequate control, add-on lixisenatide 20 µg vs placebo for 24 weeks
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=1879
Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med (2022) · Rct · n=2539
72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
N Engl J Med (2025) · Rct · n=751
Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide
Both Lixisenatide and Tirzepatide are closely matched — the best choice depends on your specific health goals.
For manage blood sugar, Tirzepatide has a higher relevance score (85 vs 50).
No known interactions between Lixisenatide and Tirzepatide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.